Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

In 2023, Novo Nordisk overtook Louis Vuitton Moët Hennessy (LVMH) to become Europe’s most valuable company, riding the meteoric rise of its weight-loss and diabetes drugs, Wegovy and Ozempic. But soon ...

Novo Nordisk is making a strategic push into India's weight-loss market to secure its position ahead of competition from ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Novo Nordisk faces resistance from Connecticut clinic in Ozempic and Wegovy dispute | LIVation admits to referencing Novo Nordisk products in past marketing but it has since been removed | Clinic ...

Novo Nordisk is still the industry leader, and its lower share price offsets a lot of the risks investors see today. Ozempic helped Novo Nordisk gain an early lead in the weight loss industry ...

Deboki: Ozempic is now a bona fide blockbuster. Novo Nordisk reported more than $40 ... clinical trials for treatment in heart, liver, and kidney conditions and a phase three trial for Alzheimers’ ...

Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease.